Latest period
−$354.17M
YoY change
+61.0%
5Y CAGR
—
Peak year (2018)
$1.21M
Latest annual
−$897.74M
Operating Cash Flow history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: −$897.74M
Operating Cash Flow growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: +61.0%
Operating Cash Flow history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | −$897.74M | +61.0% | −$340.31M | ||
| 2024 | −$557.44M | +59.0% | −$206.86M | ||
| 2023 | −$350.57M | +56.2% | −$126.17M | ||
| 2022 | −$224.40M | +52.5% | −$77.22M | ||
| 2021 | −$147.18M | +47.1% | −$47.12M | ||
| 2020 | −$100.06M | +101.7% | −$50.45M | ||
| 2019 | −$49.62M | -4190.4% | −$50.83M | ||
| 2018 | $1.21M | -104.8% | +$26.36M | ||
| 2017 | −$25.15M | — | — |
- 2025−$897.74M+61.0%
- 2024−$557.44M+59.0%
- 2023−$350.57M+56.2%
- 2022−$224.40M+52.5%
- 2021−$147.18M+47.1%
- 2020−$100.06M+101.7%
- 2019−$49.62M-4190.4%
- 2018$1.21M-104.8%
- 2017−$25.15M—
Operating Cash Flow values are taken from Revolution Medicines's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Revolution Medicines (RVMD)
Operating Cash Flow for Revolution Medicines (RVMD): headline value −$354.17M · YoY +61.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Revolution Medicines (RVMD) most recent annual operating cash flow stands at −$897.74M (2025) – surged 61.0% year-over-year.
Between 2018 and 2025, Revolution Medicines operating cash flow plunged 74110.0%, falling from $1.21M to −$897.74M.
Across the available history, operating cash flow reached its high of $1.21M in 2018 and its low of −$897.74M in 2025.
Revolution Medicines Operating Cash Flow by Year
Revolution Medicines Operating Cash Flow 2025: −$897.74M
2025's operating cash flow for Revolution Medicines came in at −$897.74M, surged 61.0% from 2024. This figure represents the lowest annual value in the available history.
Revolution Medicines Operating Cash Flow 2024: −$557.44M
Revolution Medicines posted operating cash flow of −$557.44M in 2024, surged 59.0% from 2023.
Revolution Medicines Operating Cash Flow 2023: −$350.57M
In 2023, Revolution Medicines reported operating cash flow of −$350.57M, surged 56.2% from 2022.
Revolution Medicines Operating Cash Flow 2022: −$224.40M
Revolution Medicines operating cash flow in 2022 was −$224.40M, surged 52.5% from 2021.
Revolution Medicines Operating Cash Flow 2021: −$147.18M
Revolution Medicines operating cash flow in 2021 was −$147.18M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by Operating Cash Flow
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation